Ultragenyx Pharmaceutical Receivables

As of the most recent data (June 2026), RARE shows a receivables of $200M. That compares with $130M in the prior-year period — up 59.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RARE's receivables is now $200M (was $130M) — a 59.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ultragenyx Pharmaceutical is outperforming or lagging.

Tracking RARE's receivables over time shows whether Ultragenyx Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $200M That compares with $130M in the prior-year period — up 59.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Ultragenyx Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $200M) with ownership activity and broader fundamentals.

Ultragenyx Pharmaceutical's receivables is $200M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.